Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
European Journal of Cancer (Oxford, England : 1990)|August 24, 2015
Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomasMrinal Gounder, Ved Desai, Deborah Kuk, et al.
Nature Communications|March 26, 2026
Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket studyMrinal Gounder, Patrick Schöffski, Robin L Jones, et al.
JCO Precision Oncology|December 7, 2020
Clinical Outcome of Leiomyosarcomas With Somatic Alteration in Homologous Recombination Pathway GenesEvan Rosenbaum, Philip Jonsson, Kenneth Seier, et al.
Nature Communications|January 6, 2025
MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trialMrinal Gounder, Melissa Johnson, Rebecca S Heist, et al.
Future Oncology (London, England)|April 15, 2021
Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcomaMrinal Gounder, Albiruni R Abdul Razak, Adrienne M Gilligan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2025
Milademetan in advanced solid tumors with MDM2 amplification and wild-type TP53: pre-clinical and phase 2 clinical trial resultsEcaterina E Dumbrava, Thomas E Stinchcombe, Mrinal Gounder, et al.
Investigational New Drugs|March 11, 2017
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxelLillian M Smyth, Kelsey R Monson, Komal Jhaveri, et al.
The Lancet. Oncology|October 9, 2020
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket studyMrinal Gounder, Patrick Schöffski, Robin L Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2024
A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient TumorsJ Andrew Livingston, Jean-Yves Blay, Jonathan Trent, et al.
Nature Communications|June 17, 2022
Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcomaSandra P D'Angelo, Allison L Richards, Anthony P Conley, et al.
Pageof 4